Cagrilintide

Identificazione

In breve

Cagrilintide is a long-acting analogue of amylin.

Mostrata in inglese: in questa lingua Wikipedia non ha una voce sull'argomento.

Da Wikipedia, disponibile con licenza CC BY-SA 4.0. Breve descrizione da Wikidata (CC0).

Ricerca pubblicata

I titoli sono riportati come pubblicati. Elencare un articolo non significa avallarne le conclusioni, e molti lavori sui peptidi da ricerca sono studi di laboratorio o su animali: il tipo di studio è indicato quando PubMed lo registra.

1. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityRandomized Controlled TrialMulticenter StudyClinical Trial, Phase IIIGarvey WT, Blüher M, Osorto Contreras CK et al. · N Engl J Med, 2025 · PMID 40544433 · DOI
2. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysisSystematic ReviewNetwork Meta-AnalysisYao H, Zhang A, Li D et al. · BMJ, 2024 · PMID 38286487 · DOI
3. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 DiabetesRandomized Controlled TrialClinical Trial, Phase IIIMulticenter StudyDavies MJ, Bajaj HS, Broholm C et al. · N Engl J Med, 2025 · PMID 40544432 · DOI
4. Weight management treatment in obesityReviewRubio-Herrera MA, Mera-Carreiro S · Med Clin (Barc), 2025 · PMID 40865172 · DOI
5. Beyond weight loss: multisystem benefits of obesity medicationsReviewSavas M, Kuckuck S, Boon MR et al. · Lancet Diabetes Endocrinol, 2026 · PMID 42208956 · DOI
6. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trialClinical Trial, Phase IIMulticenter StudyRandomized Controlled TrialLau DCW, Erichsen L, Francisco AM et al. · Lancet, 2021 · PMID 34798060 · DOI
7. Novel GLP-1-based Medications for Type 2 Diabetes and ObesityReviewSon JW, le Roux CW, Blüher M et al. · Endocr Rev, 2026 · PMID 41054801 · DOI
8. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trialRandomized Controlled TrialMulticenter StudyClinical Trial, Phase IIResearch Support, Non-U.S. Gov'tFrias JP, Deenadayalan S, Erichsen L et al. · Lancet, 2023 · PMID 37364590 · DOI

I primi 8 di 102 risultati, per pertinenza. Vedi tutti su PubMed.

Ricerca eseguita "Cagrilintide"[Title/Abstract]

Provenienza dei dati

Dati recuperati il 2026-10-08. Le fonti sono descritte in Info. Come vengono raccolti e controllati i dati: Metodi.